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ABSTRACT 
Objective: The main objective of this study was to investigate the potential of in situ crystallization of indomethacin, in presence or absence of 
hydrophilic materials, to improve drug dissolution with the goal of developing fast disintegrating tablets.  
Methods: Indomethacin crystals were prepared by bottom up approach. Water containing hydrophilic additive (polymer or/and surfactant) was 
added to ethanolic solution of indomethacin while stirring. The selected polymers were hydroxylpropylmethyl cellulose E5 (HPMC E5), 
polyethylene glycol 6000 (PEG6000) and polyvinylpyrrolidone K40 (PVP K40). The surfactants used were Tween80 and Glucire 44/14. The 
precipitated particles were collected and air dried. Solid state characterization were performed in addition to in vitro release studies in both acidic 
(0.1 N HCL) and alkaline medium (phosphate buffer pH 6.8). Optimized formulation was selected to develop fast disintegrating tablets. 
Results: Thermal behavior suggested modulation in crystalline nature with reduction in particle size that was confirmed by X-ray diffraction 
results. Infrared spectroscopy excluded any interaction between drug and hydrophilic excipients. Drug dissolution in acid media showed slight 
improve in drug release, while marked increase was observed in the alkaline media. Combination between Tween80 and HPMC (F7) showed the 
best dissolution parameters with 5-folds enhancement in release efficiency (RE) compared to pure drug. Formula F7 was successively used to 
formulate fast disintegrating tablets with prompted release of 58% of the loaded dose and RE of 83%. 
Conclusion: In situ crystallization of indomethacin is a good approach for enhanced dissolution rate with the presence of hydrophilic additives 
during precipitation process improving the efficiency. 
Keywords: In situ crystallization, Enhance solubility, Indomethacin, Fast disintegrating tablets  




Development of fast disintegrating tablets (FDT) has gained wide 
interest in the last few years. These tablets are claimed to undergo fast 
disintegration in the mouth with rapid drug dissolution with 
subsequent absorption reaching the systemic circulation this dosage 
form is more convenient for children and elderly patients with 
swallowing difficulties [1]. However, the poor aqueous solubility of 
many drugs provide limited candidates for such a dosage form.  
As a considerable number of newly developed chemical entities are 
classified as Class II drugs according to the biopharmaceutical 
classification system (BCS), meaning of low solubility with no 
permeability problems. Improvement of drug solubility and 
consequently its oral bioavailability remains of the utmost 
importance step in developing of new pharmaceutical product. 
There are several approaches reported in literature to enhance the 
solubility of poorly water-soluble drugs such as micronization [2], 
solid dispersion [3, 4], liquisolid tablet [5], self-emulsifying system 
[6, 7]. These techniques were chosen on the basis of certain aspects 
such as properties of drug under consideration, nature of excipients 
to be selected, and nature of intended dosage form. 
Though size reduction technique remains the most convenient and 
cost effective way for enhancing drug solubility, non-homogenous 
particle size distribution and possibleparticle agglomeration would 
decrease the surface available for dissolution [8, 9]. On the other 
hand, an amorphous solid-state powder may improve the 
bioavailability of a slightly water soluble drug due to increased 
solubility and hence absorption of the drug in the gastrointestinal 
tract. However, the amorphous form usually suffer stability and 
hygroscopicity problems leading to conversion to a more stable 
crystalline form during storage. 
In-situ micronizationcan be used as alternative to powder 
micronization. It is a relatively recent technique where micron sized 
crystals are obtained during its production without the need for any 
further particle size reduction. It is one of the easiest technique for 
producing micro crystals in one-step process that requires common 
equipment whereas other micronization techniques like milling, 
spray drying, and supercritical fluid require specialized equipment 
and containment facilities [10]. 
In situ crystallization approaches are generally based on the drug 
precipitation from a supersaturated solution of the drugusinganti-
solvent [11]. This technique produces crystals from solutions and 
can controls the crystalline properties [12, 13]. Co-precipitation of 
the drug with a stabilizer would impart a hydrophilic surface to the 
crystals that would, otherwise, aid in the dissolution step. Addition 
of hydrophilic polymers during the precipitation step would act to 
stabilizecrystal germs against possible crystal growth behavior. 
Additionally, crystalline substances obtained by this technique 
showed less cohesiveness and better flow properties [10]. In situ 
controlled crystalization was previously used to enhance dissolution 
of many drugs, such as Carbamazepine [12], ketoconazole [10], 
Glibencalmide [13] and flurbiprofen [14]. 
Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) 
commonly used as a prescription medication to reduce fever, pain, 
stiffness, and swelling. It works by inhibiting the production 
of prostaglandins. Indomethacin is classified as class II drug in the 
BCS, with poor aqueous solubility [15]. As a result of its bad 
solubility and erratic oral bioavailability, gastro-intestinal irritation 
was reported due to long contact time with the mucosa [16]. 
The objective of this work was to increase the dissolution rate of 
indomethacin with the aim of producing fast disintegrating tablets 
(FDT). This will be achieved by using in situ controlled crystallization 
technique. The effect of presence of stabilizer during the precipitation 
process on drug physical properties and dissolution behavior was also 
investigated. To find a stabilizer with high affinity to the newly created 
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high surface area, several potential stabilizing agents were compared 
including hydrophilic polymers and non-ionic surfactant. This 
technique will provide a potential for large scale production of drug 
particles with improved aqueous solubility. 
MATERIALS AND METHODS 
Indomethacin and hydroxypropylmethyl cellulose (HPMC E5) were 
obtained as a gift samples from Sigma Pharmaceutical Company, 
Quesna, Egypt. Polyvinylpyrrolidone K40 (PVP K40) was purchased 
from Sigma Chemical Co., Steinheim, Germany. Polyethylene glycol 
6000 (PEG 6000) was obtained from BDH chemical Ltd., Pool, 
England. Tween 80 was purchased from El Nasr Pharmaceutical 
chemicals Co., Cairo, Egypt. Glucire44/14 was obtained as a gift from 
Gattefosse Company, France. 
UV spectrophotometric assay of indomethacin 
The study employed a UV spectrophotometer (Thermo Fisher 
Scientific, Madison, USA). Stock solution of indomethacin (1 mg/ml) 
in ethanol was used to prepareserial dilutions to provide 
concentrations of 4, 6, 8, 10, 12, 14 and 16 µg/ml. A standard curve 
of indomethacin was constructed. The absorbance values were 
measured spectrophotometrically at λ max of 320 nm. The standard 
curve was linear (R²=0.996) over the range of concentrations used. 
Preparation of in situ indomethacin microcrystals 
The composition of the prepared formulations is presented in table 
1. The procedure was performedusing bottom-up approach that is 
generally based on the drug precipitation from a supersaturated 
solution of the drug usingde-solvent [17]. The precipitation process 
was conducted in presence or absence of hydrophilic polymer or 
nonionic surfactant. The selected surfactants were Tween80 and 
Glucire 40/14, while polymers were HPMC E5, PEG 6000, and PVP 
K40. The drug: additive weight ratio was 1:1, except for Tween and 
Glucire where a weight ratio of 1:0.5 was used. Ternary mixture of 
HPMC E5 and Tween80was prepared (table 1). The drug was 
dissolved in the least amount of ethanol. The polymer or surfactant 
was dissolved in water and added to drug solution while stirring 
using magnetic stirrer. Drug crystals were obtained as white 
precipitant. The crystals were recovered after being centrifugedat 
2000 rpm for 10 min and stored in a desicator over silica gel at room 
temperature till complete dryingand were stored in a tightly closed 
container.
  
Table 1: Composition of different formulations, together with in vitro dissolution parameters represented as percentage drug released 
after 5 min (Q5) release efficiency (RE) in acidic and basic media 
Basic media (pH 6.8) Acidic media (pH 1.2) Drug: polymer ratio Hydrophilic 
additive 
Formula 
%RE %RE Q5 Q5 
14.7(3,±0.9) 7.5(3,±0.2) 1.6(4,±0.1) 1.1(4,±0.5) - - Pure indomethacin 
25.7(3,±2.7) 18.8 (3,±0.6) 2.2(3,±0.2) 1.2(3,±0.2) - - F1 
49.0(3,±2.8) 24.8(3,±0.9) 2.9(3,±0.3) 1.4(3,±0.1) 1:1 Polyethylene glycol 6000 F2 
52.2(3,±3.1) 33.6 3,(±0.8) 12.0 (3,±0.8) 8.5(3,±1.1) 1:1 Hydroxypropylmethycellulose E5 F3 
48.5(3,±2.9) 24.7(3,±0.5) 12.8(4,±1.2) 7.2 (4±1.1) 1:1 Polyvinylpyrrolidone K40 F4 
49.2(3,±1.5) 33.4(3,±1.3) 4.4(3,±0.5) 1.5(3,±0.1) 1:0.5 Tween 80 F5 
35.9(3,±2.0) 16.7(3,±0.5) 5.6(3,±2.2) 1.7(3,±0.6) 1:0.5 Glucire 40/14 F6 
76.6(4,±1.9) 49.3(4,±1.0) 4.8(4,±0.8) 1.5(4,±0.3) 1:1:0.2 Ternary mix (drug: HPMC: Tween80) F7 
Values between brackets are number of replicates and standard deviation, respectively. 
 
Drug content 
The drug content was determined for the prepared crystals by 
dissolving an amount equivalent to 50 mg of the drug from each 
formulation in a 50 ml ethanol. After suitable dilution, drug 
concentration was determined spectrophotometrically at 320 nm. 
The experiment was performed in triplicate and the drug content 
was expressed as mg/ml concentration. 
Physical state characterization 
These studies were performed to investigate the physical properties 
of the drug after precipitation and to detect any possible interaction 
with other additives. Differential scanning calorimetry (DSC), X-ray 
diffraction and Fourier transform infrared spectroscopy (FTIR) were 
used to achieve this goal.  
Differential scanning calorimetry 
Unprocessed indomethacin, HPMC E5, PEG6000, PVP k40, and 
prepared crystals were studied regarding their thermal behavior 
using differential scanning calorimetry (DSC-60, Shimadzu, Japan). 
Aluminum pans loaded with samples equivalent to approximately 2 
mg of the drug were crimped using a Shimadzucrimper. The thermal 
behavior of each sample was investigated at a heating rate of 10 
°C/min, covering temperature ranges of 25–300 °C. Data analysis 
was conducted using the TA-60WS thermal analysis software and 
the transition midpoint (Tm) of the drug was recorded. 
X-ray powder diffraction  
Powder X-ray diffraction patterns were traced for unprocessed 
indomethacin and prepared formulations as well as pure polymers. The 
study utilized powder diffractometer (Crystal Impact, Bonn, Germany). 
Samples were loaded into aluminum containers. Scanning was 
performing datarate of 8 °/min over a 2 theta (2θ) range from 3 to 60. 
Fourier transform infrared spectroscopy 
The Fourier transform infrared (FTIR) spectra of pure indomethacin, 
pure polymers and prepared microcrystal formulations were 
recorded using FTIR spectrophotometer (FTIR-Spectrometer, 
Tensor 27, Bruker, USA). Disks of potassium bromide and tested 
sample mixtures were obtained using hydraulic press before 
scanning at a range of 4000 through 600 cm-1. 
Preparation and characterization of fast disintegrating tablets 
(FDT) 
The precipitated crystals showing the best dissolution parameters 
was selected to prepare fast disintegrating tablets by direct 
compression technique. This process employed single punch tablet 
machine (Royal Artist, Kapadia Industrial Estate, BLDG, Mumbai, 
India). The compression force was adjusted to produce tablets 
having a hardness in the range of 4–5 KP. 
Each tablet was prepared to contain an amount equivalent to 50 mg 
of the drug. The inactive components of tablets were granular 
mannitol, Avicel PH101, Ludiflash®, crospovidone and magnesium 
stearate in the concentration of 75 mg, 50 mg, 12 mg, 12 mg and 5 
mg per tablet, respectively. Mannitolasfillerthatimproves taste due 
to its mildsweet taste in addition to its known cooling sensation due 
to its negative heat of dissolution. Avicel PH101as directly 
compressible filler. Ludiflash® is a novel super-disintegrant. 
Evaluation of FDT 
The prepared tablets were evaluated regarding drug content 
uniformity, weight variation, disintegration time and dissolution 
rate. Tests procedure and limits of acceptance were in accordance to 
United States Pharmacopeia National Formulary 2000 [18]. 
Additionally, the wetting time of the tablets was also determined. 
The test was performed in petri-dish containing wetted filter paper 
with 6 ml of distilled water. A small amount of Allura red powder 
Naiem et al. 
Int J Pharm Pharm Sci, Vol 10, Issue 5, 18-23 
 
20 
was placed on the top surface of each tablet before placing over the 
wet filter paper. The time required for developing a red color on the 
surface was recorded and taken as the wetting time [19]. 
In vitro release studies 
The dissolution rate of indomethacin from different in situ 
microcrystals was determined using the USP II dissolution apparatus 
(Copley, NG 42 JY, Nottingham, UK). Raw indomethacin was used as 
control. Indomethacindis solution was evaluated both in acidic and 
basic dissolution medium. The acidic medium was 0.1 N HCl (pH 1.2) 
simulating gastric condition, and the alkaline medium was phosphate 
buffer pH 6.8 containing 0.15% sodium dodecylsulfate simulating 
intestinal conditions. The paddle speed was adjusted to 100 rpm and 
dissolution medium (900 ml) was maintained at 37 °C. Following 
loading the drug (50 mg) or its equivalent from crystal formulations, 
samples of 5 ml each were withdrawn at a predetermined time 
interval for a length of 60 min, and were replaced with fresh 
dissolution medium. Fast dissolving tablets were tested in the buffer 
solution using the same dissolution conditions. After filtering through 
0.45 mm Whatman membrane filter, each sample was analyzed 
spectrophotometricaly for drug content. The cumulative amounts drug 
dissolved (expressed as % of the total drug load) were plotted as a 
function of time to obtain the dissolution profiles. Dissolution 
parameters were calculated and compared. 
Statistical analysis 
All experiments were conducted in triplicates and Statistical analysis 
employed Student t-test. Results were quoted as significant when 
P<0.05. 
RESULTS AND DISCUSSION 
Solid state characterization of the prepared microcrystals 
Drug content of the prepared crystals were in the range of 97-99% 
w/w, excluding any possibility for segregation of drug or additives 
during preparation (table 1).  
Differential scanning calorimetry (DSC) 
DSC of pure indomethacin and different formulations are shown in fig. 
1. High phase transition temperature (Tm) and peak sharpening would 
indicate high degree of crystalline structure of a substance. Peak 
shifting to a lower Tm and/or broadening would designate reduced 
drug crystallinity [19]. Unprocessed indomethacin showed a 
characteristic endothermic peak with a Tmbeingrecorded at161 °C 
indicating the crystalline nature of the drug (fig. 1A). The recorded 
endothermic peak correlates well with values published by other 
investigators [20, 21]. Thermogram for pure PEG 6000 showed a 
sharp endothermic peak with Tm of about60 °C (fig. 1A), agreeing with 
reported transition behavior of the same polymer [13]. For pure HPMC 
the thermal event showed a broad endotherm with onset of 39.2 °C 
with an end set of 80.1 °C. Similarly, PVP thermogram recorded a 
broad endothermic peak with onset of30.9 °C and endset of 81.0 °C. 
These broaden peaks represent the desorption of the bound water 




Fig. 1: Examples of DSC traces of pure indomethacin, 
polyethylene glycol 6000 (PEG 6000), hydroxypropyl methyl 
cellulose E5 (HPMC), polyvinylpyrrolidone (PVP) and different 
formulations. For detailed formulations refer to table 1 
 
Regarding plain indomethacin crystals (F1, in situ crystals without 
polymer) the endothermic peak can be detected at the same Tm with 
reduced sharpness and slight peak broadening (fig. 1A). This would 
suggest possible reduction in crystal size during the in situ 
crystallization. Regarding the prepared crystals in presence of 
hydrophilic additives, all formulations showed a slight shift in Tm to 
a lower value compared to that without polymer and unprocessed 
drug. Presence of surfactants during in situ crystallization (Tween 
80 "F2" and Glucire 44/14 "F6") resulted in slight reduction in 
transition temperature with Tm appearing at159 °C (fig. 2A and B). 
This reduction accompanied by peak broadening with a slight 
reduction in peak area and enthalpy.  
In situ precipitation in presence of polymer showed considerable 
change in thermal behavior different from that of unprocessed drug 
and polymer. For F3, prepared using PEG 6000, thermogram showed 
broad symmetric endothermic peak at 159.1 °C with an onset of 145 
°C and endset of 175 °C (fig. 1A). For F5, prepared using PVP, similar 
thermal pattern was observed with melting transition of the drug 
appearing at 158.5 °C (fig. 1B). 
For F4, prepared using HPMC with a Tm of 143 °C considerable peak 
broadening and reduced enthalpy. The maximum effect was 
observed for formula F7, precipitated drug in presence of both 
HPMC and Tween 80, where the endothermic peak underwent 
significant broadening with the melting transition of drug is almost 
abolished. This thermal pattern suggests reduced particle size of 
drug crystals. Additionally, transformation of the drug into 
amorphous form with probable modification of the crystalline 
structure is also a possibility [14, 20]. This requires further 
confirmation by with other instrumental techniques. 
X-ray powder diffraction (XRPD) 
The diffractograms of pure drug, polymers and different 
formulations are presented in fig. 3. The diffraction pattern of 
unprocessed drug showed numerous diffraction peaks at angle (2θ) 
of 9 °, 11.5 °, 16.8 °, 19.6 °, 21.7 °and 26.6 °. This reflects the 
crystalline nature of the drug. This diffraction pattern is similar to 
reported data for the same drug and indicates that majority of 
indomethacin is present in itsgamma form [20-23]. In situ 
crystallization of the drug in presence or absence of hydrophilic 
polymers and/or surfactant resulted in diffractograms with 
diffraction peaks at the same position of those recorded in case of 
the pure drug but with lower intensity (fig. 2). It worth noting that 
the reduction in peak intensity was higher for crystals precipitated 
in presence of the hydrophilic additives. This verifies that a 
considerable amount of drugispresent in crystalline state in addition 
to the amorphous form. Meantime, possible reduction in the particle 
size after in situ crystallization can also be considered. Reduced 
intensity of the diffraction peaks was previously explained as an 
indication of reduced particle size [14, 24]. The highest reduction in 
peak intensity was noticed for crystals prepared in presence of 
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HPMC and Tween80 (F7). Thisfindingis in good agreement with DSC 
data. It is important to highlight that the reduced peak intensity may 
indicate the possible partial formation of amorphous form during 




Fig. 2: X-ray diffractograms of (A) pure indomethacin and different 
formulations (B) pure polyethylene glycol 6000 (PEG 6000), 
hydroxypropylmethyl cellulose (HPMC) and polyvinylpyrrolidone 
(PVP). For detailed formulations refer to table 1 
 
Fourier transform infrared spectroscopy (FTIR) 
The infrared study was performed to examine any possible 
interaction between pure drug and additives. Fig. 3 shows the FTIR 
spectra of indomethacin, pure polymers and the prepared 
formulations. 
Pure indomethacin spectra showed characteristic peaks represented 
as aromatic C-H stretching at 3020 cm–1, C-H stretching vibrations at 
2965 cm–1, C =O stretching vibrations shown at 1760 cm–1. Peak at 
1599 cm–1for aromatic c≡c stretching. The asymmetric aromatic O-C 
stretching reveals at1261 cm–1and that for symmetric aromatic O-H 
stretching vibration at1086 cm–1. This spectra in good agreement 
with published data [21]. 
The FTIR spectrum of pure PVP K40 was characterized by its 
carbonyl group which appeared at lower frequency of 1655 cm-1 due 
to hydrogen bonding with the adsorbed water. There was a broad 
band at 3429 cm-1 for the hydrogen bonded OH group indicating 
hygroscopic property of PVP [26]. For HPMC, a broad band of 
hydroxyl group was shown in the range of 3100–3600 cm-1. This 
agrees with the published spectrum of the same polymer [26, 27]. 
The spectrum of PEG 6000 reveals broad band at 3446 cm-1, 2887 
cm-1, 1113 cm-1for the OH group, aliphatic C-H stretching and C–O 
stretching, respectively. This finding is in good correlation with the 
previous published data of the same polymer [27]. FTIR spectrums 
of tested formulations revealed the main absorption bands of 
indomethacinwith no significant changes compared with the 
spectrum of pure drug. This would suggest absence of any possible 




Fig. 3: FTIR spectra of unprocessed indomethacin and different 
formulations together with pure polyethylene glycol (PEG 
6000), hydroxypropyl methyl cellulose (HPMC), and 
polyvinylpyrrolidone (PVP)) together. For detailed 
formulations refer to table 1 
 
In vitro drug release studies 
The dissolution profiles of indomethacin from the rawpowderand 
powders prepared by in situ controlled crystallization in presence of 
different hydrophilic additives are presented as percentage drug 
released versus time plots in fig. 4. The dissolution parameters were 
extracted from the profiles and represented as the percentage 
amountofdrug released after 5 min (Q5) in acid and basic conditions. 
The percentage release efficiencies (RE) in both media were 
calculated from the area under the dissolution profile of each 
formulation at time t and expressed as the percentage of the area of 
the rectangle described by 100% dissolution in the same time [28]. 
These parameters are presented in table 1. 
In acidic medium, unprocessed drug showedvery slow drug 
dissolution with a Q5 of 1% and a RE of about 2%. This poor 
dissolution can be attribute to the hydrophobic nature of the drug as 
well as the reported limited solubility in acidic conditions [29]. 
Preparation of plain drug crystals slightly improved drug release 
compare to control (fig. 4A and table 1). The in situ crystallization of 
indomethacin in presence of hydrophilic polymers and/or surfactant 
was studied with the aim to impart hydrophilic characters to the 
crystal surface and to reduce the possible particles aggregation up 
on storage. PVP k40, HPMC E5 and PEG 6000 were selected as the 
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hydrophilic polymers, while Tween 80 and Glucire 44/14 was used 
as an example for nonionic surfactants according to the formulations 
presented in table 1. Additionally ternary mixture of drug, HPMC 
and Tween 80 was also investigated. 
In situ crystals prepared in presence of hydrophilic polymer or 
surfactant showed a trend of increased Q5 and RE, except for F4 and 
F5 prepared in presence of HPMC and PVP, respectively. The latter 
two formulations showed the highest significant increased 
dissolution parameters (P<0.05) with about 7-fold and 12-fold 




Fig. 4: In vitro drug dissolution of indomethacin from 
unprocessed form and different drug crystal formulationsin 
acidic (A) and basic (B) media, together with in vitro dissolution 
of fast disintegrating tablets (B) (n=3) 
 
Contrary to acidic environment, dissolution of pure indomethacin 
and prepared formulations in alkaline media (pH 6.8) showed a 
better dissolution behavior. Unprocessed drug showed Q5 and RE of 
about 7.5 and 15%, respectively. Plain indomethacin microcrystals 
(F1) showed a similar Q5 value to that of control; however 2-fold 
enhancement in release efficiency was noted. This result could be 
due to decreased particle size during the precipitation step with 
subsequent increase in the surface area, as evidenced by DSC and x-
ray results. Partial change in crystalline nature of the drug is also a 
possible explanation. 
All formulations prepared in presence of hydrophilic additives 
showed a considerable increase in dissolution parameters over 
unprocessed drug (fig. 4A and table 1). There was a significant 
increaseinQ5and RE relative to pure drug (P<0.05). The ternary 
mixture of indomethacin, HPMC and Tween 80 (F7) showed the 
highest dissolution parameters with a Q5 and RE of 49% and 76%, 
respectively. The superiority of formulations prepared by in situ 
crystallization of the drug in presence of hydrophilic substance 
could be due to the possible adsorption of the hydrophilic molecules 
on the microstructure of the crystal surface during the precipitation 
and separation processes [14]. Such adsorption could be due to 
polar and nonpolar interactions of the hydrophilic molecules and 
drug such as Van der Waals, hydrogen bonding and/or hydrophobic 
interaction [30]. Such interaction between the hydrophilic additive 
and the surface of the newly formed crystals will improve the crystal 
behavior by two possible mechanisms. Firstly, increasing the 
hydrophilicity and consequently wettability of drug particles. 
Secondary, sterically stabilizing crystals against agglomeration 
because of their hydrophobic surface. Therefore, all these factors 
(increased surface wettabilityand reduced crystal size) would act 
synergistically. For the ternary system in F7, presence of hydrophilic 
polymer HPMC and surfactant resulted in augmented effect in 
enhancing drug dissolution.  
The overall results thus reflect the potential of the controlled 
precipitation technique as a tool to improve drug dissolution 
behavior by proper manipulation of polymer type and 
concentration. Formula F7, showed best dissolution parameters, was 
selected to prepare fast disintegrated tablets. 
Characterization of fast disintegration tablets  
Regarding the quality control studies, tablets complied with the US 
Pharmacopeia requirements for acceptable tablets batch. For the 
weight variation, the deviation from the mean tablet weight was<2% 
as a reflection of good powder flowability. The recorded content 
uniformity values were in the range of 97±2.6%, the friability was 
found to be 0.9%, indicating acceptable resistance of tablets to 
handling. The wetting time was 30±0.2 secondsThis short wetting 
time could be due to reduced hydrophobicity of the drug after 
controlled precipitation in presence of hydrophilic polymers. The 
average disintegration time of 50 second was noted and can be 
attributed to the presence of super-disintegrant, Ludiflash®, that 
aids in rapid tablet break down. 
The dissolution profile for FDT is presented in fig. 5B. Tablets 
exhibited a relatively better dissolution behavior compared with the 
unprocessed drug powder. This is reflected by recorded Q5and RE of 
58% and 83%, respectively. The enhanced dissolution of 
indomethacin from FDT compared to the F7 powder, optimized 
formula used in tablet preparation, can be explained by the 
adsorption of the drug on the surface of tablet excipients with 
subsequent rapid dispersion in the dissolution medium. This also 
proof that the compression force used during tablet manufacturing 
didn't affect the dissolution rate of the obtained drug crystals. 
CONCLUSION  
In situ controlled crystallization in presence of hydrophilic polymer 
and/or surfactants is a useful tool to enhance dissolution rate of 
indomethacin. Such enhancement, particularly in the basic media, 
can be attributed to adsorption of hydrophilic substance over drug 
particle. Reduced particle size after precipitation can provide 
another explanation for such improvement. Partial formation of 
amorphous drug particles is also a possibility. The optimized ternary 
drug/HPMC/Tween80 mixture, showing the best dissolution 
parameters, was successfully formulated as fast disintegrating 
tablets with subsequent rapid drug release.  
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